Search

Your search keyword '"Ailawadhi S"' showing total 210 results

Search Constraints

Start Over You searched for: Author "Ailawadhi S" Remove constraint Author: "Ailawadhi S" Database MEDLINE Remove constraint Database: MEDLINE
210 results on '"Ailawadhi S"'

Search Results

1. Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry.

2. The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events.

3. Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma.

4. The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the Connect Ⓡ MM Registry.

5. Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis.

6. Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation.

7. Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma.

8. Use of Hematopoietic Cell Transplant for Hematologic Cancers by Race, Ethnicity, and Age.

9. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.

10. Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel.

11. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma.

12. Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia.

13. Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities.

14. Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data.

15. Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma.

16. Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities.

17. Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable.

18. A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia.

19. An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.

20. Development and validation of algorithms for identifying lines of therapy in multiple myeloma using real-world data.

21. MicroRNA and long non-coding RNA analysis in IgM-monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis.

22. Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives.

23. Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM Registry.

24. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.

25. Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relapsed/Refractory Multiple Myeloma.

26. Acute esophageal stricture after bone marrow transplant.

27. Assessment of second primary malignancies among treated and untreated patients with chronic lymphocytic leukemia using real-world data from the USA.

28. Superior detection rate of plasma cell FISH using FACS-FISH.

29. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.

30. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma.

32. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas.

33. Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment.

34. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.

35. Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety.

36. Multiple Myeloma: Current Clinical Landscape and Compounding Costs.

37. Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience.

38. The digital divide: Racial disparities in adoption and utilization of health information technology among patients with lymphoid cancers.

39. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma.

40. Global disparities in patients with multiple myeloma: a rapid evidence assessment.

41. Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.

43. Post-Autologous Hematopoietic Cell Transplant Care in the "Home Sweet Home" Setting: A Treatment Paradigm Shift.

44. Partnering With All Patients: Ensuring Shared Decision Making and Evidence-Based Management for Underrepresented Groups With Multiple Myeloma.

45. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma.

46. Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience.

47. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

48. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.

49. Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience.

50. Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies.

Catalog

Books, media, physical & digital resources